Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6555886 | 1.00 | KDM4E (0.36) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL6523894 | 0.86 | CYP1A2 (0.40) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL7205409 | 0.86 | CYP1A2 (0.40) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL30741903 | 0.85 | ALDH1A1 (0.41) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL30741902 | 0.83 | KDM4E (0.33) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4428946 | 0.82 | KDM4E (0.46) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4456772 | 0.81 | MAPT (0.52) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL221191 | 0.81 | MAPT (0.52) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL221192 | 0.81 | MAPT (0.52) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4258837 | 0.81 | CHRM1 (0.43) | MAPTNFKB1BLMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC | 2025-08-14 | — | — | US | claimed |
| EP-4561372-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024026124-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | PETERSON MATTHEW (US) | 2024-02-01 | — | — | WO | claimed |
| EP-1185510-B1 | S-NITROSO- AND S-NITRO-N-ACYL-L-CYSTEINE-ESTER-DERIVATIVES AS PHARMACOLOGICAL SUBSTANCES AND MEDICAMENTS CONTAINING SAID COMPOUNDS | TSIKAS DIMITRIOS (DE) | 2004-03-03 | — | — | EP | claimed |
| US-6613937-B2 | In particular for transdermal, oral, rectal and inhalational application | TSIKAS DIMITRIOS (DE) | 2003-09-02 | — | — | US | claimed |
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC | 2025-08-14 | — | — | US | disclosed |
| EP-4561372-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | Nature's Fusions, LLC (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026124-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | PETERSON MATTHEW (US) | 2024-02-01 | — | — | WO | disclosed |
| US-10408843-B2 | Compositions and methods for detecting S-nitrosylation and S-sulfinylation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-09-10 | — | — | US | disclosed |
| US-10408843-B2 | Compositions and methods for detecting S-nitrosylation and S-sulfinylation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-09-10 | — | — | US | disclosed |
| US-20170192012-A1 | COMPOSITIONS AND METHODS FOR DETECTING S-NITROSYLATION AND S-SULFINYLATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-07-06 | — | — | US | disclosed |
| US-20170192012-A1 | COMPOSITIONS AND METHODS FOR DETECTING S-NITROSYLATION AND S-SULFINYLATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-07-06 | — | — | US | disclosed |
| US-20170192012-A1 | COMPOSITIONS AND METHODS FOR DETECTING S-NITROSYLATION AND S-SULFINYLATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-07-06 | — | — | US | disclosed |
| US-20160084845-A1 | COMPOSITIONS AND METHODS FOR DETECTING S-NITROSYLATION AND S-SULFINYLATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-03-24 | — | — | US | disclosed |
| US-20160084845-A1 | COMPOSITIONS AND METHODS FOR DETECTING S-NITROSYLATION AND S-SULFINYLATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-03-24 | — | — | US | disclosed |
| US-20160084845-A1 | COMPOSITIONS AND METHODS FOR DETECTING S-NITROSYLATION AND S-SULFINYLATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-03-24 | — | — | US | disclosed |
| EP-1185510-B1 | S-NITROSO- AND S-NITRO-N-ACYL-L-CYSTEINE-ESTER-DERIVATIVES AS PHARMACOLOGICAL SUBSTANCES AND MEDICAMENTS CONTAINING SAID COMPOUNDS | TSIKAS DIMITRIOS (DE) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255843-A1 | COMPOSITIONS COMPRISING CYSTEINE PRODRUGS AND METHODS USING THEREOF | AHCY, MGMT, CBS | KDM4E 2170/4885MAPT 2515/4885THRB 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.